Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* upper age to 18 years~* mammary adenocarcinoma nonmetastatic and histologically proven~* wait under an adjuvant or neoadjuvant chemotherapy according to the following conventional scheme: 3 cycles of F5-Fluorouracil, epirubicin and cyclophosphamide 100 (500 or 5-Fluorouracil 600 mg / m² J1, Epirubicin 100 mg / m² J1, Cyclophosphamide 500 or 600 mg / m² J1 or 3 cycles of Epiribucin and Cyclophosphamide 100) followed by 3 cycles of docetaxel, 100 mg / m², +/- trastuzumab if Her2+++~* Patient with the capacity/faculties to understand a newsletter and sign an informed consent~* Patient receiving social coverage~* Patient who can be treated and followed in the center for a period of at least one year~* WHO scale 0 or 1~Exclusion Criteria:~* Age below 18 years~* Diseases of the scalp or whatever hair-showing against helmet or alopecia~* Using pre nail resin before and per chemotherapy~* mammary adenocarcinoma stage IV~* Indication of docetaxel for cancer of another organ than breast~* Treatment processing or programmed during chemotherapy with an innovative molecule being evaluated~* Raynaud's syndrome, cold agglutinin disease, cryoglobulinemia and cryofibrinogenemia.~* Uncontrolled severe arterial disease.~* Presence of a device\> grade 1 neuropathy before the start of chemotherapy~* Patient unable to submit the protocol followed for psychological, social, family or geographical~* Patient with an incompatible underlying disease or concomitant with the inclusion in the trial, whether psychiatric or somatic~* Patient trust, guardianship, under legal protection measure, deprived of freedom~* Male~* Criteria for non randomization (before the first course of docetaxel) :~  * Presence of peripheral neuropathy\> grade 1 after the first 3 cycles of 5-Fluorouracil, epirubicin and cyclophosphamide 100.~ * Presence of a nail or skin toxicity\> grade 1 after 3 cycles of 5-Fluorouracil, epirubicin and cyclophosphamide 100.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard cryoprotection (Type: ACTIVE_COMPARATOR): Proposal helmet without mittens and booties
- Cryoprotection with mittens and booties (Type: EXPERIMENTAL): Standard cryoprotection with mittens and booties

Based on this trial design, predict the completion outcome and termination type (if applicable).